Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| ciliated cell | 5 studies | 28% ± 10% | |
| type I pneumocyte | 5 studies | 21% ± 4% | |
| type II pneumocyte | 5 studies | 22% ± 5% | |
| glutamatergic neuron | 4 studies | 60% ± 27% | |
| GABAergic neuron | 4 studies | 58% ± 25% | |
| club cell | 4 studies | 28% ± 6% | |
| endothelial cell | 3 studies | 22% ± 2% | |
| epithelial cell | 3 studies | 25% ± 7% | |
| retinal rod cell | 3 studies | 23% ± 6% | |
| T follicular helper cell | 3 studies | 18% ± 1% | |
| hepatocyte | 3 studies | 28% ± 7% | |
| astrocyte | 3 studies | 40% ± 16% | |
| oligodendrocyte precursor cell | 3 studies | 34% ± 14% | |
| respiratory goblet cell | 3 studies | 36% ± 10% | |
| basal cell | 3 studies | 24% ± 5% | |
| interneuron | 3 studies | 51% ± 20% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| pancreas | 100% | 991.50 | 328 / 328 | 99% | 18.16 | 177 / 178 |
| thymus | 100% | 437.42 | 651 / 653 | 100% | 27.68 | 603 / 605 |
| prostate | 96% | 708.50 | 234 / 245 | 99% | 33.11 | 498 / 502 |
| kidney | 100% | 696.96 | 89 / 89 | 93% | 13.50 | 842 / 901 |
| lung | 93% | 223.50 | 537 / 578 | 96% | 17.67 | 1110 / 1155 |
| liver | 100% | 676.96 | 226 / 226 | 83% | 12.22 | 336 / 406 |
| stomach | 75% | 282.28 | 268 / 359 | 91% | 14.18 | 259 / 286 |
| breast | 64% | 309.66 | 294 / 459 | 97% | 29.95 | 1086 / 1118 |
| intestine | 48% | 131.74 | 467 / 966 | 97% | 16.56 | 510 / 527 |
| bladder | 52% | 138.52 | 11 / 21 | 92% | 15.12 | 464 / 504 |
| adrenal gland | 63% | 90.22 | 163 / 258 | 76% | 10.02 | 175 / 230 |
| esophagus | 48% | 190.88 | 687 / 1445 | 86% | 10.10 | 157 / 183 |
| ovary | 13% | 12.69 | 24 / 180 | 95% | 14.64 | 407 / 430 |
| uterus | 17% | 33.88 | 29 / 170 | 84% | 18.09 | 385 / 459 |
| tonsil | 0% | 0 | 0 / 0 | 91% | 18.22 | 41 / 45 |
| skin | 72% | 701.68 | 1305 / 1809 | 4% | 0.32 | 20 / 472 |
| brain | 69% | 142.78 | 1822 / 2642 | 2% | 0.14 | 17 / 705 |
| lymph node | 0% | 0 | 0 / 0 | 69% | 9.85 | 20 / 29 |
| spleen | 63% | 75.33 | 151 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 34% | 61.73 | 318 / 929 | 0% | 0 | 0 / 0 |
| adipose | 30% | 42.71 | 356 / 1204 | 0% | 0 | 0 / 0 |
| heart | 3% | 2.81 | 24 / 861 | 0% | 0 | 0 / 0 |
| blood vessel | 2% | 2.92 | 25 / 1335 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 1% | 0.09 | 1 / 80 |
| muscle | 0% | 0.36 | 3 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0019369 | Biological process | arachidonic acid metabolic process |
| GO_0016042 | Biological process | lipid catabolic process |
| GO_0005811 | Cellular component | lipid droplet |
| GO_0016020 | Cellular component | membrane |
| GO_0017064 | Molecular function | fatty acid amide hydrolase activity |
| Gene name | FAAH2 |
| Protein name | Fatty-acid amide hydrolase 2 (EC 3.5.1.99) (Amidase domain-containing protein) (Anandamide amidohydrolase 2) (Oleamide hydrolase 2) |
| Synonyms | AMDD |
| Description | FUNCTION: Catalyzes the hydrolysis of endogenous amidated lipids like the sleep-inducing lipid oleamide ((9Z)-octadecenamide), the endocannabinoid anandamide (N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine), as well as other fatty amides, to their corresponding fatty acids, thereby regulating the signaling functions of these molecules . Hydrolyzes monounsaturated substrate anandamide preferentially as compared to polyunsaturated substrates. . |
| Accessions | ENST00000374900.5 Q6GMR7 |